Voyager Therapeutics (VYGR) to Release Earnings on Tuesday

Voyager Therapeutics (NASDAQ:VYGR) is projected to release its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect Voyager Therapeutics to post earnings of ($0.48) per share and revenue of $9.50 million for the quarter.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.18). Voyager Therapeutics had a negative return on equity of 27.36% and a negative net margin of 126.49%. The business had revenue of $6.47 million during the quarter, compared to the consensus estimate of $13.55 million. On average, analysts expect Voyager Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Voyager Therapeutics Stock Performance

Shares of VYGR opened at $2.96 on Friday. The company’s fifty day moving average is $3.19 and its 200 day moving average is $3.70. Voyager Therapeutics has a fifty-two week low of $2.64 and a fifty-two week high of $8.53. The stock has a market capitalization of $163.81 million, a PE ratio of -2.03 and a beta of 0.90.

Institutional Trading of Voyager Therapeutics

A number of hedge funds have recently added to or reduced their stakes in VYGR. AQR Capital Management LLC lifted its position in shares of Voyager Therapeutics by 179.3% during the first quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock valued at $1,674,000 after buying an additional 317,927 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Voyager Therapeutics during the first quarter valued at about $218,000. Finally, Acadian Asset Management LLC increased its holdings in shares of Voyager Therapeutics by 863.3% during the first quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock valued at $778,000 after acquiring an additional 206,758 shares in the last quarter. 48.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $13.39.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.